RHOC's Emily Simpson Responds to Critics Who Blame Her for Son's Eating Disorder
During the RHOC Season 19 premiere, Emily revealed that her ten-year-old son Luke was diagnosed with ARFID, or avoidant restrictive food intake disorder. Since then, she and husband Shane Simpson have been on a journey to figure out what's best for their son. And hurtful comments have no place in the plan.
Emily Simpson explains why son's eating disorder is different to body image issues
'I have to say, I've had some people say negative things about the eating disorder, and they'll make a correlation between me having surgery or me losing weight,' Emily exclusively told Us Weekly. 'This has nothing to do with a child wanting to lose weight or having a body image. This is a neurodivergent disorder that has to do with his brain and how he operates.'
She further clarified that Luke's diagnosis 'has nothing to do with me and losing weight or gaining weight.' There are aspects of ARFID that are less clear currently. Emily admitted that she is still looking for answers.
'We definitely know that he has ARFID. The ARFID has a lot of symptoms that overlap with autism,' she explained. 'We did take him to a specialist to be tested. He did some very extensive testing that comes up later in the season. I'm still not really clear on a lot of things.'
Thankfully, the RHOC star has gotten more online support than anything. Emily is part of several parental support groups of children with ARFID.
Catch The Real Housewives of Orange County Thursdays at 9/8c on Bravo. It streams on Hayu in the UK and Ireland.
TELL US – WHAT IS YOUR REACTION TO THE TROLLING? WHAT DO YOU THINK OF EMILY'S RESPONSE?
The post RHOC's Emily Simpson Responds to Critics Who Blame Her for Son's Eating Disorder appeared first on Reality Tea.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
8 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Upturn
8 hours ago
- Business Upturn
QuasarMD Unveils Advanced Full-Body Light Therapy Mat to Support Aging Wellness
CHINO, Calif., July 29, 2025 (GLOBE NEWSWIRE) — QuasarMD LLC, a leader in light-based wellness technologies, announces the launch of its Full-Body Light Therapy Mat , a clinically validated, non-invasive solution designed to address the evolving wellness needs of aging adults. The full-body mat features 2,052 high-efficiency LEDs delivering dual-wavelength therapy: 660nm red light for surface-level benefits, and 850nm near-infrared (NIR) for deep penetration. Both wavelengths are clinically proven to provide cellular-level therapeutic effects. Specifically designed for aging users, the system provides gentle yet effective relief for common age-related concerns including joint stiffness, muscle fatigue, circulation challenges, and chronic conditions like arthritis or back and knee pain. Designed with Aging in Mind 'Chronic pain, sleepless nights, and reduced mobility are common challenges as we age,' said a spokesperson for QuasarMD. 'Our full-body light therapy mat was specifically developed to help older adults restore their vitality through scientifically validated, non-invasive technology that integrates effortlessly into daily life.' The QuasarMD Full-Body Light Therapy Mat is FDA-cleared device meeting professional-grade standards. Its home operation couldn't be simpler – just lie down and press a button. Featuring an innovative wrap-around design, the mat cossets the body in comfort to ensure complete light exposure from head to toe. Users can easily customize their therapy experience by adjusting time, intensity, and pulse settings for each session. It has a multi-layered fabric design with an inner layer of TPU that enhances light retention, improving both durability and light efficiency. Additionally, it is waterproof and easy to clean, making it convenient for daily use by seniors and caregivers alike. The QuasarMD mat is more than just a health tool – it's a companion for active aging, offering a drug-free, non-invasive way to manage pain, inflammation, and fatigue. Its gentle warmth and therapeutic light not only ease physical discomfort but also enhance mental well-being, improve blood circulation, promote deep relaxation, and foster an enduring sense of vitality – all essential components of healthy aging. 'Today's aging population is more proactive about wellness than ever,' noted the spokesperson. 'Caregivers, wellness professionals, and older adults increasingly demand safe, science-backed solutions that are both effective and convenient for home use. The evidence supporting red and NIR light therapy is robust – and truly empowering.' 'That's why we've developed this solution: to help people naturally manage discomfort, improve sleep quality, and support long-term vitality – all without medications or invasive treatments.' About the Company QuasarMD LLC is a California-based wellness technology company specializing in FDA-cleared light therapy devices that blend clinical efficacy with user-friendly design. Dedicated to working on well-being through the life stages, it has kept innovating non-invasive devices that assist in recovery, wellness, and vigor through light. The Full-Body Light Therapy Mat is now available for purchase at the official QuasarMD shop and through Amazon . Media Contact:QuasarMD LLC Email: [email protected] Phone: 917-426-2860 Address: 15515 Dupont Avenue, Chino, CA 91710, USA Website:
